中性粒细胞与淋巴细胞比值及其动态变化对经肝动脉化疗栓塞术治疗的肝细胞癌患者预后的预测价值

王文军; 赵艳; 夏冬东; 王恩鑫; 刘雷; 韩国宏

doi:10.3969/j.issn.1001-5256.2016.06.024

中性粒细胞与淋巴细胞比值及其动态变化对经肝动脉化疗栓塞术治疗的肝细胞癌患者预后的预测价值

DOI: 10.3969/j.issn.1001-5256.2016.06.024

第四军医大学西京消化病医院消化介入科

基金项目:

国家自然科学基金(81172145,81420108020)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2271
- HTML全文浏览量: 35
- PDF下载量: 446
- 被引次数: 0
出版历程
- 出版日期: 2016-06-20

Predictive value of neutrophil-lymphocyte ratio and its dynamic change in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

Research funding:

摘要

摘要: 目的探讨中性粒细胞与淋巴细胞比值（NLR）及其动态变化在经肝动脉化疗栓塞术（TACE）治疗肝细胞癌（HCC）中的预测价值。方法将2010年1月-2014年12月在第四军医大学西京消化病医院诊断为HCC并接受TACE治疗的患者纳入研究,收集基线、术后3 d,术后1个月的中性粒细胞与淋巴细胞比值（NLR）等因素。采用受试者工作特征曲线确定NLR的最佳界值。计量资料组间比较采用t检验,计数资料采用χ2检验,生存时间组间比较应用Kaplan-Meier法,单因素、多因素Cox回归分析进行预后分析。结果共纳入427例HCC患者。基线NLR的中位值为2.4;术后3 d,NLR值增高,中位值达6.2;术后1个月,NLR值降至基线水平。基线、术后3 d和术后1个月预测生存的最佳分界值分别为2.5、9.7和2.5。基线、术后3 d、术后1个月低NLR组和高NLR组中位生存时间差异有统计学意义（χ2=10.529、8.388、6.679,P值均<0.05）。多因素Cox回归分析显示:基线NLR>2.5是HCC患者生存差的独立预测因素。基线和术后3 d NLR都低组、基线或术后3 d NLR高组...
- 癌,肝细胞 /
- 化学栓塞,治疗性 /
- 中性粒细胞淋巴细胞比值 /
- 预测
Abstract: Objective To investigate the predictive value of neutrophil- lymphocyte ratio(NLR) and its dynamic change in patients with hepatocellular carcinoma(HCC) undergoing transarterial chemoembolization(TACE).Methods The patients who were diagnosed with HCC and treated with TACE in Xijing Hospital of Digestive Disease of Fourth Military Medical University from January 2010 to December2014 were enrolled.The factors including NLR were recorded at baseline and 3 days and 1 month after TACE.The receiver operating characteristic(ROC) curve was used to determine the cut- off value of NLR.The t- test was used for comparison of continuous data between groups,the chi- square test was used for comparison of categorical data between groups,the Kaplan- Meier method was used to calculate survival rates,and univariate and multivariate Cox regression analyses were used for prognostic analysis.Results A total of 427 patients were enrolled.The median value of baseline NLR was 2.4;at 3 days after surgery,NLR increased and the median value reached 6.2;at 1month after surgery,NLR decreased to the baseline level.The cut- off values at baseline,3 days after surgery,and 1 month after surgery were 2.5,9.7,and 2.5,respectively.At baseline,3 days after surgery,and 1 month after surgery,the median survival time showed significant differences between the low- NLR group and the high- NLR group(χ2= 10.529,8.388,and 6.679,all P < 0.05).The multivariate Cox regression analysis showed that the baseline NLR > 2.5 was the independent predictor for survival difference in HCC patients.In the group with low NLR at baseline and 3 days after surgery,the group with high NLR at baseline or 3 days after surgery,and the group with high NLR at baseline and 3 days after surgery,the median survival time was 28.0,21.0,and 10.1 months,respectively,and showed a significant difference between groups(χ2= 19.846,P < 0.001).In the group with low NLR at baseline and 1 month after surgery,the group with high NLR at baseline or 1 month after surgery,and the group with high NLR at baseline and 1 month after surgery,the median survival time was 29.4,21.0,and 15.4 months,respectively,and showed a significant difference between groups(χ2= 11.424,P = 0.003).Conclusion Baseline NLR and its dynamic change can be used to predict the prognosis in HCC patients receiving TACE.
- carcinoma /
- hepatocellular /
- chemoembolization /
- therapeutic

HTML全文

参考文献(38)

[1]CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.

[2]LLOVET JM,REAL MI,MONTANA X,et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet,2002,359(9319):1734-1739.

[3]LO CM,NGAN H,TSO WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology,2002,35(5):1164-1171.

[4] CAMMA C,SCHEPIS F,ORLANDO A,et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma:meta-analysis of randomized controlled trials[J].Radiology,2002,224(1):47-54.

[5]LLOVET JM,BRUIX J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival[J].Hepatology,2003,37(2):429-442.

[6] BRUIX J,SHERMAN M,American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53(3):1020-1022.

[7]European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].JHepatol,2012,56(4):908-943.

[8]LUO Y,SHE DL,XIONG H,et al.Pretreatment neutrophil to lymphocyte ratio as a prognostic predictor of urologic tumors:a systematic review and meta-analysis[J].Medicine(Baltimore),2015,94(40):e1670.

[9] SUN W,ZHANG L,LUO M,et al.Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma:neutrophil-lymphocyte ratio and platelet-lymphocyte ratio[J].Head Neck,2016,38(Suppl 1):e1332-e1340.

[10]TURNER N,WONG HL,TEMPLETON A,et al.Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria[J].Int J Cancer,2016,138(3):671-678.

[11] WU G,YAO Y,BAI C,et al.Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients[J].Thorac Cancer,2015,6(3):275-287.

[12] YODYING H,MATSUDA A,MIYASHITA M,et al.Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio in oncologic outcomes of esophageal cancer:a systematic review and meta-analysis[J].Ann Surg Oncol,2016,23(2):646-654.

[13]HUANG ZL,LUO J,CHEN MS,et al.Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization[J].J Vasc Interv Radiol,2011,22(5):702-709.

[14]MANO Y,SHIRABE K,YAMASHITA Y,et al.Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma:a retrospective analysis[J].Ann Surg,2013,258(2):301-305.

[15]MOTOMURA T,SHIRABE K,MANO Y,et al.Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment[J].J Hepatol,2013,58(1):58-64.

[16]PINATO DJ,SHARMA R.An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma[J].Transl Res,2012,160(2):146-152.

[17]SULLIVAN KM,GROESCHL RT,TURAGA KK,et al.Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma:a Western perspective[J].J Surg Oncol,2014,109(2):95-97.

[18]BRUIX J,REIG M,RIMOLA J,et al.Clinical decision making and research in hepatocellular carcinoma:pivotal role of imaging techniques[J].Hepatology,2011,54(6):2238-2244.

[19] TEMPLETON AJ,MCNAMARA MG,SERUGA B,et al.Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors:a systematic review and meta-analysis[J].J Natl Cancer Inst,2014,106(6):dju124.

[20] LOI S,SIRTAINE N,PIETTE F,et al.Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicinbased chemotherapy:BIG 02-98[J].J Clin Oncol,2013,31(7):860-867.

[21]NEAGOE PE,BRKOVIC A,HAJJAR F,et al.Expression and release of angiopoietin-1 from human neutrophils:intracellular mechanisms[J].Growth Factors,2009,27(6):335-344.

[22]GONG Y,KOH DR.Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model[J].Cell Tissue Res,2010,339(2):437-448.

[23]FU SJ,SHEN SL,LI SQ,et al.Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy[J].Med Oncol,2013,30(4):721.

[24]GOMEZ D,FARID S,MALIK HZ,et al.Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma[J].World J Surg,2008,32(8):1757-1762.

[25]LAI Q,CASTRO SANTA E,RICO JURI JM,et al.Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer[J].Transpl Int,2014,27(1):32-41.

[26]XIAO GQ,LIU C,LIU DL,et al.Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation[J].World J Gastroenterol,2013,19(45):8398-8407.

[27] WANG GY,YANG Y,LI H,et al.A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation[J].PLo S One,2011,6(9):e25295.

[28]BERTUZZO VR,CESCON M,RAVAIOLI M,et al.Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers[J].Transplantation,2011,91(11):1279-1285.

[29] FAN W,ZHANG Y,WANG Y,et al.Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization[J].PLo S One,2015,10(3):e0119312.

[30]MCNALLY ME,MARTINEZ A,KHABIRI H,et al.Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization[J].Ann Surg Oncol,2013,20(3):923-928.

[31] ZHENG YB,ZHAO W,LIU B,et al.The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib[J].Asian Pac J Cancer Prev,2013,14(9):5527-5531.

[32]LI X,CHEN ZH,MA XK,et al.Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma[J].Tumour Biol,2014,35(11):11057-11063.

[33] OH BS,JANG JW,KWON JH,et al.Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma[J].BMC Cancer,2013,13(1):78.

[34]HARIMOTO N,SHIRABE K,NAKAGAWARA H,et al.Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation:with special reference to neutrophil/lymphocyte ratio[J].Transplantation,2013,96(11):1008-1012.

[35]HALAZUN KJ,HARDY MA,RANA AA,et al.Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma[J].Ann Surg,2009,250(1):141-151.

[36] XIAO WK,CHEN D,LI SQ,et al.Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma:a meta-analysis[J].BMC Cancer,2014,14(1):117.

[37]KUDO M,IMANAKA K,CHIDA N,et al.Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J].Eur JCancer,2011,47(14):2117-2127.

[38] LENCIONI R,LLOVET JM,HAN G,et al.Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC:the SPACE trial[J].J Hepatol,2016,64(5):1090-1098.

施引文献

资源附件(0)

访问统计